ReviewFrontiers in immunology2026
Significance of innate immune surveillance in emphysematous pancreatitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emphysematous pancreatitis (EP) is a severe and life-threatening complication of pancreatitis characterized by gas formation within pancreatic tissues, which often results from bacterial infection. This condition poses significant challenges due to its rapid progression and high mortality rate. Innate immunity plays a pivotal role in the pathogenesis, progression, and potential treatment of EP as the body's first line of defense against infectious agents. Current research has elucidated various mechanisms through which innate immune components contribute to inflammatory responses and microbial clearance in EP. Despite advances in understanding pancreatic inflammation, the specific contributions of innate immunity to EP's development, progression, and clinical outcomes remain not fully elucidated. Incorporating insights into innate immune markers may enhance early detection and prognostic accuracy. Moreover, therapeutic strategies targeting innate immune modulation hold promise for improving management and reducing morbidity associated with EP. This review comprehensively summarizes the mechanisms by which innate immune responses contribute to EP pathogenesis. It also highlights emerging diagnostic biomarkers and imaging techniques that facilitate early detection and discusses novel immunomodulatory therapies targeting innate immune responses. This review is a scoping review based on a structured literature search (see Methods). We aim to provide a framework and identify future research directions to improve clinical management and outcomes for patients with EP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.